Home > Healthcare > Biotechnology > Biopharma > Antibody Therapy Market

Antibody Therapy Market Share

Report ID: GMI5195
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Antibody Therapy Market Share

The key players are actively engaged in strategic collaborations, product launches, and acquisitions to strengthen their market position. The market also witnesses a surge in biosimilar competition, intensifying rivalry. Strong R&D initiatives, coupled with regulatory approvals, show the dynamic competition, fostering advancements in antibody therapies and shaping the market's evolving competitive landscape.

Market players operating in the antibody therapy is as mentioned below:

F. Hoffmann-La Roche Ltd.
AbbVie, Inc.
Amgen Inc.
Bristol-Myers Squibb Company
Johnson & Johnson Services, Inc.
Seagen
Merck & Co., Inc.
Regeneron Pharmaceuticals Inc.
Novartis AG
AstraZeneca
Eli Lilly and Company
GlaxoSmithKline plc.
Takeda Pharmaceutical Company Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global antibody therapy industry size accounted for USD 214.7 billion in 2022 and is expected to reach USD 638.2 billion by end of 2032, favored by the approval of new therapies and drugs for the treatment of diseases.

The hospitals segment held the major market share of 47.6% in 2022 and will continue to grow owing to its role as a primary healthcare provider for severe and chronic diseases. Hospitals have specialized infrastructure, skilled personnel, and advanced technology required for administering and monitoring antibody therapies.

North America antibody therapy market is expected surpass USD 284 billion by 2032, owing to the robust regulatory framework as well as rising investment in novel antibody therapy development by key players.

F. Hoffmann-La Roche Ltd., AbbVie, Inc., Amgen Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Seagen, Merck & Co., Inc., Regeneron Pharmaceuticals Inc., and Novartis AG among others.